Pyridine → HCID 135524127, compound
Reaction equation
[Cl:1][C:2]1[CH:11]=[C:10]([O:12][CH2:13][C:14]2[O:18][C:17]([C:19]3([CH3:25])[CH2:24][CH2:23][CH2:22][CH2:21][CH2:20]3)=[N:16][C:15]=2[CH3:26])[CH:9]=[CH:8][C:3]=1[C:4]([NH:6][OH:7])=[NH:5].N1C=CC=CC=1.[C:33]1([O:39]C(Cl)=O)C=CC=CC=1.N12CCCN=C1CCCCC2>ClCCl.C(#N)C>[Cl:1][C:2]1[CH:11]=[C:10]([O:12][CH2:13][C:14]2[O:18][C:17]([C:19]3([CH3:25])[CH2:24][CH2:23][CH2:22][CH2:21][CH2:20]3)=[N:16][C:15]=2[CH3:26])[CH:9]=[CH:8][C:3]=1[C:4]1[NH:5][C:33](=[O:39])[O:7][N:6]=1Participants
7
Procedure
1.39 g 2-Chloro-N-hydroxy-4-[4-methyl-2-(1-methyl-cyclohexyl)-oxazol-5-ylmethoxy]-benzamidine were dissolved in 10 ml dichloromethane. 0.36 ml pyridine and 0.56 ml phenylchloroformate were added and the mixture stirred at room temperature for ten minutes. The mixture was diluted by the addition of 30 ml acetonitrile and 2.75 ml 1,8-Diazabicyclo[5.4.0]undec-7-ene were added. The mixture was stirred at room temperature for 10 minutes. The mixture was evaporated in vacuo and the resulting crude material was purified by reversed phase HPLC to obtain 950 mg 3-{2-Chloro-4-[4-methyl-2-(1-methyl-cyclohexyl)-oxazol-5-ylmethoxy]-phenyl}-4H-[1,2,4]oxadiazol-5-one as an amorphous lyophilisate.
Workup
- additionwere added
- stirringThe mixture was stirred at room temperature for 10 minutes
- customThe mixture was evaporated in vacuo
- customthe resulting crude material was purified by reversed phase HPLC
Sources & evidence
- ORD record
- ord-8b948aaab7d34bf6ba644cfdc2b891d6
- Source dataset
- uspto-grants-2010_05
- Patent number
- US07709481B2
Reaction notes
Loading…